Benralizumab in Severe Eosinophilic Asthma: Toward Disease Control and Evolving Treatment Paradigms Authors: Angelantonio Maglio, Carolina Vitale, Luisa Oriana D’Auria, Valeria Longobardi, Antonio Franzese, Corrado Pelaia, Girolamo Pelaia, Cecilia Calabrese, Alessandro Vatrella Published: 2026 ABSTRACT AbstractSevere eosinophilic asthma (SEA) is a type-2 inflammatory phenotype driven by persistent eosinophilia, characterized by frequent exacerbations, progressive lung function decline, and substantial oral corticosteroid (OCS) dependence, for which conventional therapies remain insufficient in a significant minority of patients. Benralizumab—a humanized, afucosylated anti-interleukin-5 receptor alpha (IL-5Rα) monoclonal antibody—achieves near-complete depletion of eosinophils and basophils through dual receptor blockade and afucosylation-enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), producing one of the most extensive anti-eosinophilic effects among currently approved biologics. Pivotal Phase 3 trials (SIROCCO, CALIMA, ZONDA) demonstrated annual exacerbation rate reductions of up to 51%, robust OCS-sparing with complete elimination in 52.7% of OCS-dependent patients, and significant improvements in forced expiratory volume in 1 second (FEV1). Long-term extension data over five years (MELTEMI) confirmed sustained efficacy and safety, without evidence of adverse consequences attributable to chronic eosinophil depletion. Landmark studies including PONENTE, SHAMAL, and ABRA have further extended benralizumab’s clinical impact: enabling structured OCS elimination, demonstrating that well-controlled patients can reduce inhaled corticosteroids to as-needed therapy, and establishing biologic-based treatment of acute eosinophilic exacerbations as a viable new approach. Real-world evidence consistently corroborates trial findings, with clinical remission—defined as the composite achievement of exacerbation freedom, OCS independence, symptom control, and preserved lung function—reported in 17–44% of patients at 12 months and up to 91% in selected longer-term cohorts. Beyond asthma, benralizumab demonstrates meaningful activity in comorbid chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and eosinophilic esophagitis. This review comprehensively examines benralizumab’s molecular pharmacology, pivotal and real-world clinical evidence, comorbidity management, and its central role in driving the paradigm shift from symptom control toward clinical remission in severe eosinophilic airway disease. Introduction Asthma affects an estimated 300–400 million individuals worldwide, representing one of the most prevalent chronic respiratory diseases. While most patients achieve acceptable disease control with standard inhaled corticosteroids (ICS) and long-acting beta-2 agonists (LABA), approximately 5–10% remain refractory to conventional therapies.1 These patients—classified as having severe or difficult-to-treat asthma—disproportionately contribute to healthcare utilization, emergency department visits, hospitalization, and disability. Among severe asthma phenotypes, severe eosinophilic asthma (SEA) is among the most prevalent, best-characterized, and most therapeutically actionable subtypes, representing a substantial proportion of type-2–driven severe disease. SEA is defined by persistent blood and/or airway eosinophilia, driven by a type-2 (T2) cytokine milieu including IL-4, IL-5, and IL-13, predominantly secreted by Th2 CD4+ T cells and type-2 innate lymphoid cells (ILC2s).2,3 IL-5 is the master regulator of eosinophil biology, governing maturation in the bone marrow, systemic mobilization, tissue recruitment, and extended survival in the airways— where activated eosinophils release cytotoxic mediators that perpetuate airway hyperresponsiveness (AHR), mucus plugging, and airway remodeling.4,5 The recognition of eosinophilic airway inflammation as a mechanistically distinct and therapeutically targetable process has driven the development of precision biologic therapies. Anti-IL-5 monoclonal antibodies (mepolizumab, reslizumab) reduce circulating eosinophils by 50–80% through cytokine neutralization. Benralizumab, uniquely, binds the IL-5 receptor alpha (IL-5Rα) directly, blocking IL-5 signaling while simultaneously inducing ADCC-mediated eosinophil apoptosis through its afucosylated Fc domain—achieving near-complete (>90%) depletion of eosinophils and basophils from blood, bone marrow, and airway tissue.6,7 Benralizumab (Fasenra®; AstraZeneca, Cambridge, UK; Kyowa Kirin, Tokyo, Japan) was approved by the US FDA and EMA in 2017 for add-on maintenance treatment of patients aged ≥12 years with severe, uncontrolled eosinophilic asthma, administered as 30 mg subcutaneously every 4 weeks for the first three doses, then every 8 weeks. Beyond the traditional endpoints of exacerbation reduction and OCS-sparing, benralizumab has contributed to a broader, class-wide shift toward clinical remission as an aspirational therapeutic goal—a composite state of no exacerbations, no OCS use, well-controlled symptoms, and preserved lung function.8,9 Notably, this shift is not unique to benralizumab: remission has been evaluated as an explicit therapeutic goal across the type-2 biologic class.10 The current biologic armamentarium for severe asthma comprises anti-IgE (omalizumab), anti-IL-5/IL-5Rα agents (mepolizumab, reslizumab, benralizumab), anti-IL-4Rα (dupilumab), and anti-TSLP (tezepelumab) therapies, each targeting distinct nodes of the type-2 inflammatory cascade. Within this landscape, benralizumab is distinguished by its dual mechanism—direct IL-5Rα blockade combined with afucosylation-enhanced ADCC—and by an unusually broad clinical-development programme spanning oral corticosteroid elimination, inhaled corticosteroid de-escalation, treatment of acute eosinophilic exacerbations, and several eosinophil-associated comorbidities; this breadth provides the rationale for the present focused review. For this narrative review, we searched PubMed/MEDLINE for English-language pivotal randomised controlled trials, long-term extension studies, real-world cohorts, and consensus documents on benralizumab in severe eosinophilic asthma and related eosinophilic conditions, prioritising phase 3 trials, large real-world programmes, and recent consensus statements; other biologics are discussed where relevant for comparative context. This review provides a comprehensive, evidence-based examination of benralizumab pharmacology, complete pivotal trial evidence, long-term safety data, real-world effectiveness, management of eosinophilic comorbidities, the evolving concept of clinical remission, and its strategic positioning within the modern severe asthma therapeutic landscape. Pathophysiology of Severe Eosinophilic Asthma: The IL-5 Axis SEA is characterized by a complex, self-reinforcing inflammatory network. Airway epithelial damage and allergen exposure trigger the release of alarmins—thymic stromal lymphopoietin (TSLP), IL-33, and IL-25—that activate ILC2s and prime adaptive Th2 responses. The resulting cytokine cascade elevates IL-5 levels, which act on IL-5Rα-expressing eosinophil precursors in the bone marrow to drive differentiation into mature eosinophils, their release into circulation, and subsequent recruitment into bronchial tissue via eotaxin-1/2/3 and RANTES gradients.4,11 Tissue eosinophils release an armamentarium of destructive mediators: major basic protein (MBP), eosinophil-derived neurotoxin (EDN), eosinophil cationic protein (ECP), eosinophil peroxidase, and cysteinyl leukotrienes. These agents damage bronchial epithelium, impair mucociliary clearance, stimulate goblet cell metaplasia and mucus hypersecretion, sensitize sensory nerves driving AHR, and promote subepithelial fibrosis and airway smooth muscle hypertrophy.5,12 At the structural level, eosinophil-derived TGF-β1 drives myofibroblast activation and subepithelial collagen deposition, whereas eosinophil peroxidase cross-links extracellular matrix proteins—collectively contributing to the fixed airflow limitation that characterizes advanced eosinophilic asthma. Mucus plugging is a key mechanism linking eosinophilic inflammation to airflow obstruction: eosinophil peroxidase–derived oxidants promote mucus plug formation, and high CT-quantified mucus plug scores are associated with severe airflow limitation and airway eosinophilia.13 Advanced imaging studies have provided direct evidence linking eosinophilic inflammation to specific physiological abnormalities. Hyperpolarized 129Xe MRI ventilation defect percentage (VDP) and CT-quantified mucus plug scores independently predict ACQ-6 response to benralizumab and correlate with airway obstruction severity.14 These findings establish mucus plug resolution and improved ventilation homogeneity as key mechanistic endpoints of anti-eosinophilic therapy. An emerging concept concerns two functionally distinct eosinophil populations: inflammatory eosinophils (iEOs), expressing high surface IL-5Rα and contributing to tissue damage, and homeostatic eosinophils (hEOs) with potential roles in tissue repair and mucosal immunity.15 Mepolizumab selectively depletes iEOs while preserving hEOs; benralizumab—by virtue of direct IL-5Rα binding and ADCC—depletes both populations completely. Higher residual iEO proportions following mepolizumab treatment correlate with poorer asthma control, suggesting that complete eosinophil depletion may confer additional clinical benefits in selected patients.15 Benralizumab: Pharmacology and Mechanism of Action Molecular Structure and Afucosylation Benralizumab is a fully humanized IgG1κ monoclonal antibody engineered through targeted afucosylation—the removal of fucose residues from Fc domain oligosaccharides via expression in FUT8-deficient CHO cells. The absence of core fucose markedly increases IgG1 affinity for FcγRIIIa (CD16a) on effector cells and thereby enhances ADCC potency—a principle originally established using afucosylated anti-IL-5Rα antibodies.6,16 For benralizumab specifically, this afucosylation confers an approximately 5- to 50-fold enhancement of ADCC activity relative to the fucosylated antibody, while preserving normal pharmacokinetics.7 Dual Effector Mechanism Benralizumab operates through two mechanistically complementary pathways. First, Fab-domain binding to IL-5Rα directly blocks IL-5 from engaging its receptor, preventing downstream JAK1/2-STAT5 and RAS-MAPK signaling that drives eosinophil survival, degranulation, and cytokine secretion. This receptor blockade also prevents basophil IL-5 signaling. Second, the afucosylated Fc domain engages FcγRIIIa on NK cells and macrophages, triggering ADCC: NK cells release perforin and granzymes that induce eosinophil apoptosis (confirmed by upstream caspase-3/7 activation and cytochrome c release), while macrophages perform ADCP—phagocytosis of apoptotic eosinophils—clearing cellular debris and dampening residual inflammation.17 A recently characterized amplification loop enriches benralizumab’s cytotoxic effect: activated macrophages secrete TNF, which engages TNFR1 on eosinophils to further drive caspase activation, while NK cell-derived IFN-γ amplifies macrophage TNF production—creating a paracrine circuit that broadens and deepens eosinophil elimination.17 Afucosylation potentiates all three mechanisms simultaneously. The consequence of this dual mechanism is among the most pronounced in the anti-IL-5 class: near-complete depletion of blood eosinophils (>95%) within 1–2 weeks of the first injection, sustained through the treatment period.7 Bone marrow eosinophil progenitors are also depleted, truncating the eosinophil production pipeline. Airway tissue eosinophils, confirmed by endobronchial biopsy and nasal polyp histology, are reduced to undetectable levels with continued treatment.18 The dual effector mechanism and multi-compartmental eosinophil depletion achieved by benralizumab are illustrated in Figure 1. Figure 1Mechanisms of action of benralizumab and multi-compartmental eosinophil depletion in severe eosinophilic asthma. Benralizumab, an afucosylated humanized anti-IL-5Rα monoclonal antibody (mAb), exerts its therapeutic effect through two primary effector mechanisms. First, it induces antibody-dependent cell-mediated cytotoxicity (ADCC) via engagement of the FcγRIIIa receptor on natural killer (NK) cells, triggering degranulation of cytotoxic granules and release of interferon-gamma (IFN-γ), leading to eosinophil apoptosis. Second, it promotes antibody-dependent cellular phagocytosis (ADCP) through interaction with FcγRIIIa on macrophages, which also express tumour necrosis factor receptor 1 (TNFR1) and release tumour necrosis factor-alpha (TNF-α). By binding to IL-5Rα — the alpha subunit of the interleukin-5 receptor, which forms a heterodimer with the common beta chain (βc) — benralizumab additionally blocks IL-5-mediated pro-survival and maturation signalling. These combined mechanisms result in profound eosinophil depletion across three anatomical compartments: (i) reduced eosinophil precursor maturation in the bone marrow, (ii) rapid elimination of circulating eosinophils in peripheral blood, and (iii) sustained depletion of tissue eosinophils in the airways. The downstream clinical impact includes reduction of airway eosinophilic inflammation, decreased frequency of acute exacerbations, diminished dependence on oral corticosteroids (OCS), improvement in lung function and overall asthma control, and a favorable tolerability profile with low immunogenicity.The diagram illustrates the mechanisms of action of benralizumab in eosinophil depletion. Benralizumab, an afucosylated humanized anti-IL-5R alpha monoclonal antibody, engages Fc gamma RIIIa receptors on natural killer cells and macrophages. On natural killer cells, it induces antibody-dependent cell-mediated cytotoxicity, leading to degranulation and release of interferon-gamma, causing eosinophil apoptosis. On macrophages, it promotes antibody-dependent cellular phagocytosis, interacting with Fc gamma RIIIa and tumor necrosis factor receptor 1, releasing tumor necrosis factor-alpha. Benralizumab blocks IL-5-mediated signaling by binding to IL-5R alpha, reducing eosinophil precursor maturation in the bone marrow, rapid elimination of circulating eosinophils in blood vessels and sustained depletion in airway tissues. The clinical impact includes reduced airway eosinophilic inflammation, decreased exacerbations, improved lung function and low immunogenicity.Diagram showing benralizumab′s action in eosinophil depletion via ADCC and ADCP mechanisms across compartments.Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; βc, common beta chain; FcγRIIIa, Fc gamma receptor IIIa; IFN-γ, interferon-gamma; IL-5, interleukin-5; IL-5Rα, interleukin-5 receptor alpha subunit; mAb, monoclonal antibody; NK cell, natural killer cell; OCS, oral corticosteroids; TNF-α, tumour necrosis factor-alpha; TNFR1, tumour necrosis factor receptor 1. Mechanisms of action of benralizumab and multi-compartmental eosinophil depletion in severe eosinophilic asthma. Benralizumab, an afucosylated humanized anti-IL-5Rα monoclonal antibody (mAb), exerts its therapeutic effect through two primary effector mechanisms. First, it induces antibody-dependent cell-mediated cytotoxicity (ADCC) via engagement of the FcγRIIIa receptor on natural killer (NK) cells, triggering degranulation of cytotoxic granules and release of interferon-gamma (IFN-γ), leading to eosinophil apoptosis. Second, it promotes antibody-dependent cellular phagocytosis (ADCP) through interaction with FcγRIIIa on macrophages, which also express tumour necrosis factor receptor 1 (TNFR1) and release tumour necrosis factor-alpha (TNF-α). By binding to IL-5Rα — the alpha subunit of the interleukin-5 receptor, which forms a heterodimer with the common beta chain (βc) — benralizumab additionally blocks IL-5-mediated pro-survival and maturation signalling. These combined mechanisms result in profound eosinophil depletion across three anatomical compartments: (i) reduced eosinophil precursor maturation in the bone marrow, (ii) rapid elimination of circulating eosinophils in peripheral blood, and (iii) sustained depletion of tissue eosinophils in the airways. The downstream clinical impact includes reduction of airway eosinophilic inflammation, decreased frequency of acute exacerbations, diminished dependence on oral corticosteroids (OCS), improvement in lung function and overall asthma control, and a favorable tolerability profile with low immunogenicity. Pharmacokinetics Following subcutaneous administration of 30 mg, benralizumab exhibits approximately 59% bioavailability, consistent with a two-compartment pharmacokinetic model. The terminal half-life is approximately 15.5 days. Steady-state serum concentrations are achieved by week 24, with a median trough of approximately 385 ng/mL in the CRSwNP OSTRO trial.18 Fixed dosing without weight-based adjustment is supported by population pharmacokinetic modeling. No clinically significant drug-drug interactions have been identified. Pivotal Phase 3 Clinical Trial Program The clinical development program for benralizumab represents one of the most comprehensive in severe asthma, encompassing phase 3 pivotal trials, extension studies up to five years, phase 3b trials, and dedicated investigations in OCS-dependent and ICS-reduction populations. Table 1 summarizes key studies. Table 1Summary of Key Phase 3 and 3b/4 Clinical Studies of Benralizumab in Severe Eosinophilic AsthmaTrial (Year)nDesignEosinophil Inclusion CriteriaStudy DurationPrimary EndpointKey Outcomes (Q8W)SIROCCO (2016)191205Phase 3 RCTBEC ≥300 cells/µL (primary population); high-dose ICS+LABA48 wkAER (BEC ≥300)AER −51%; FEV1 +0.159 L; symptom improvementCALIMA (2016)201306Phase 3 RCTBEC ≥300 cells/µL (primary population); high-dose ICS+LABA56 wkAER (BEC ≥300)AER −28%; FEV1 +0.116 L; symptom improvementZONDA (2017)21220Phase 3 RCTBEC ≥150 cells/µL; OCS-dependent SEA28 wkMedian OCS dose reductionMedian OCS −75%; 52.7% eliminated OCS; AER −55%BORA (2019)221926Open-label extension (SIROCCO/CALIMA)As per parent trials56 wk (extension)Long-term safetyConsistent safety; ~75% exacerbation-free; efficacy maintainedMELTEMI (2021)23446Open-label extensionAs per parent trialsUp to 5 yrLong-term safetyNo new safety signals; AE rates stable; ≥75% exacerbation-free annuallyANDHI (2021)24656Phase 3b RCTBEC ≥150 cells/µL; SEA24 wkAER; SGRQAER −49%; SGRQ −8.11 points; early effect (wks 1–4)PONENTE (2022)25598Open-label, structured OCS taperingBEC ≥150 cells/µL (or historical ≥300); OCS-dependentVariable (induction + OCS taper)Proportion eliminating OCS62.9% eliminated OCS; 81.9% ≤5 mg/day; adrenal monitoringSHAMAL (2024)26168Phase 4 RCTBenralizumab-controlled SEA on high-dose ICS/formoterol48 wkProportion reducing ICS92% reduced ICS; 61% to as-needed only; control maintainedABRA (2025)27158RCT (acute eosinophilic exacerbation)Acute exacerbation with blood eosinophilia90 dTreatment failure at 90 dOR 0.26 vs prednisolone; superior VAS symptom controlNotes: Superscript numbers refer to the corresponding entries in the reference list.Abbreviations: AER, annual exacerbation rate; AE, adverse event; BEC, blood eosinophil count; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; OCS, oral corticosteroid; OR, odds ratio; Q8W, every 8 weeks; RCT, randomised controlled trial; SEA, severe eosinophilic asthma; SGRQ, St George’s Respiratory Questionnaire; VAS, visual analogue scale. Table 1Summary of Key Phase 3 and 3b/4 Clinical Studies of Benralizumab in Severe Eosinophilic AsthmaTrial (Year)nDesignEosinophil Inclusion CriteriaStudy DurationPrimary EndpointKey Outcomes (Q8W)SIROCCO (2016)191205Phase 3 RCTBEC ≥300 cells/µL (primary population); high-dose ICS+LABA48 wkAER (BEC ≥300)AER −51%; FEV1 +0.159 L; symptom improvementCALIMA (2016)201306Phase 3 RCTBEC ≥300 cells/µL (primary population); high-dose ICS+LABA56 wkAER (BEC ≥300)AER −28%; FEV1 +0.116 L; symptom improvementZONDA (2017)21220Phase 3 RCTBEC ≥150 cells/µL; OCS-dependent SEA28 wkMedian OCS dose reductionMedian OCS −75%; 52.7% eliminated OCS; AER −55%BORA (2019)221926Open-label extension (SIROCCO/CALIMA)As per parent trials56 wk (extension)Long-term safetyConsistent safety; ~75% exacerbation-free; efficacy maintainedMELTEMI (2021)23446Open-label extensionAs per parent trialsUp to 5 yrLong-term safetyNo new safety signals; AE rates stable; ≥75% exacerbation-free annuallyANDHI (2021)24656Phase 3b RCTBEC ≥150 cells/µL; SEA24 wkAER; SGRQAER −49%; SGRQ −8.11 points; early effect (wks 1–4)PONENTE (2022)25598Open-label, structured OCS taperingBEC ≥150 cells/µL (or historical ≥300); OCS-dependentVariable (induction + OCS taper)Proportion eliminating OCS62.9% eliminated OCS; 81.9% ≤5 mg/day; adrenal monitoringSHAMAL (2024)26168Phase 4 RCTBenralizumab-controlled SEA on high-dose ICS/formoterol48 wkProportion reducing ICS92% reduced ICS; 61% to as-needed only; control maintainedABRA (2025)27158RCT (acute eosinophilic exacerbation)Acute exacerbation with blood eosinophilia90 dTreatment failure at 90 dOR 0.26 vs prednisolone; superior VAS symptom controlNotes: Superscript numbers refer to the corresponding entries in the reference list.Abbreviations: AER, annual exacerbation rate; AE, adverse event; BEC, blood eosinophil count; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; OCS, oral corticosteroid; OR, odds ratio; Q8W, every 8 weeks; RCT, randomised controlled trial; SEA, severe eosinophilic asthma; SGRQ, St George’s Respiratory Questionnaire; VAS, visual analogue scale. Summary of Key Phase 3 and 3b/4 Clinical Studies of Benralizumab in Severe Eosinophilic Asthma Notes: Superscript numbers refer to the corresponding entries in the reference list. Abbreviations: AER, annual exacerbation rate; AE, adverse event; BEC, blood eosinophil count; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; OCS, oral corticosteroid; OR, odds ratio; Q8W, every 8 weeks; RCT, randomised controlled trial; SEA, severe eosinophilic asthma; SGRQ, St George’s Respiratory Questionnaire; VAS, visual analogue scale. SIROCCO (NCT01928771) SIROCCO was a landmark phase 3, randomized, double-blind, placebo-controlled trial enrolling 1,205 patients (aged 12–75 years) with severe, uncontrolled asthma on high-dose ICS plus LABA with ≥2 prior-year exacerbations. The primary endpoint was annual exacerbation rate (AER) at 48 weeks in patients with blood eosinophils ≥300 cells/μL. Benralizumab 30 mg Q8W significantly reduced AER by 51% versus placebo (RR 0.49, 95% CI 0.37–0.64; p<0.0001) and improved pre-bronchodilator FEV1 by 0.159 L (p<0.001). Morning peak expiratory flow improvement was detectable as early as day 2 post-injection, achieving a clinically meaningful threshold within 3 weeks.19,28 CALIMA (NCT01914757) CALIMA enrolled 1,306 patients with severe, uncontrolled asthma on medium- to high-dose ICS plus LABA, with a 56-week treatment period. In the primary analysis population (eosinophils ≥300 cells/μL, high-dose ICS), benralizumab Q8W reduced AER by 28% (RR 0.72, 95% CI 0.54–0.95; p=0.019) and improved FEV1 by 0.116L.20 Pooled SIROCCO/CALIMA analyses demonstrated a clear eosinophil-dependent treatment gradient: patients with eosinophils ≥450 cells/μL and ≥3 prior exacerbations derived the greatest benefit (AER reduction 55–63%).29 Benralizumab efficacy was preserved irrespective of atopy status, IgE level, and age of asthma diagnosis.30 ZONDA (NCT02075255) ZONDA specifically targeted the OCS-dependent SEA population: 220 patients requiring ≥7.5 mg/day prednisone equivalent entered this 28-week trial. Benralizumab Q8W produced a median OCS reduction of 75% versus 25% with placebo (p<0.001). Critically, 52.7% of benralizumab-treated patients completely eliminated OCS, compared to 19.0% on placebo—an odds ratio of 4.09 (p<0.001). Concomitant AER reduction of 55% was observed, further demonstrating the systemic anti-inflammatory impact of near-complete eosinophil depletion.21 BORA Extension (NCT02258542) Patients completing SIROCCO or CALIMA were invited into BORA, providing up to 2 years of continuous benralizumab exposure for 1,576 patients. Safety profiles remained consistent with pivotal studies; no new consequences of long-term eosinophil depletion were observed. Approximately 75% of patients remained exacerbation-free annually, and FEV1 improvements were maintained or amplified in patients who were newly initiated on benralizumab from placebo.22 MELTEMI—Five-Year Safety and Efficacy The MELTEMI open-label extension enrolled 446 patients from predecessor studies, with 35.2% receiving benralizumab for ≥4 years. Adverse event rates (28.5–32.4 per 100 patient-years) and serious adverse event rates (6.3–8.4 per 100 patient-years) were stable over time and did not increase with exposure. Only 8 patients discontinued due to adverse events over the entire observation period. Exacerbation elimination was maintained in ≥75% of patients annually, confirming the durability of benralizumab’s therapeutic effect without safety compromise.23 ANDHI (NCT03170271) This phase 3b trial enrolled 656 adults with SEA over 24 weeks, focusing on onset of effect, HRQoL, and nasal polyposis subgroups. Benralizumab reduced AER by 49% (RR 0.51; p<0.0001) and improved SGRQ total score by −8.11 points (p<0.0001).24 Notably, statistically significant improvements in FEV1, PEF, ACQ-6, Clinician and Patient Global Impression of Change, and SNOT-22 (in the nasal polyposis subgroup) were observable within weeks 1–4 of treatment—a uniquely rapid onset consistent with the kinetics of eosinophil depletion.24 PONENTE (NCT03557307) This multicenter, open-label, single-arm study (n=598, 17 countries) prospectively evaluated a structured, individualized OCS reduction algorithm in benralizumab-treated patients with OCS-dependent SEA. A critical finding was the detection of adrenal insufficiency in 60% of patients at first cortisol assessment— underscoring the widespread and frequently unrecognized HPA axis suppression from chronic OCS use.25 Using a personalized dose-reduction schedule with cortisol monitoring and ACTH stimulation testing, 62.9% of patients eliminated OCS and 81.9% achieved elimination or ≤5 mg/day. The annualised exacerbation rate during OCS tapering was 0.63, with 75% experiencing no exacerbations.25 SHAMAL (NCT04159519) SHAMAL addressed the novel question of whether ICS can be substantially reduced in SEA patients well controlled on benralizumab. In this phase 4 open-label trial (n=168, 4 countries), patients randomized to the tapering arm reduced their ICS-formoterol dose stepwise from high-dose to medium-dose, low-dose, and ultimately to as-needed only. Ninety-two percent achieved at least one dose reduction; 61% successfully tapered to as-needed ICS/formoterol (the lowest possible controller regimen), with 96% maintaining these reductions at week 48, and 91% remaining exacerbation-free throughout.26 These findings establish that, for patients achieving good asthma control on benralizumab, high-dose ICS may no longer be necessary—a fundamental challenge to the conventional step-up approach to severe asthma management. ABRA (NCT04098718) Perhaps the most practice-changing recent trial, ABRA evaluated benralizumab 100 mg as treatment for acute eosinophilic exacerbations of asthma and COPD (blood eosinophils ≥300 cells/μL at presentation). In 158 patients (randomized 1:1:1 to benralizumab plus prednisolone, benralizumab alone, or prednisolone alone), the pooled benralizumab group demonstrated markedly fewer treatment failures at 90 days (45% vs 74%; OR 0.26, 95% CI 0.13–0.56; p=0.0005) and superior VAS symptom control at day 28 Benralizumab was well tolerated; hyperglycaemia and sinusitis adverse events were confined to the prednisolone arm. These results establish eosinophil-guided single-injection biologic therapy as a new standard for managing acute eosinophilic respiratory exacerbations.27 Biomarkers, Patient Selection, and Predictors of Response Blood Eosinophil Count Blood eosinophil count (BEC) is the most validated biomarker for anti-IL-5 pathway therapy selection. Post hoc pooled SIROCCO/CALIMA analyses confirmed a progressive dose-response relationship: AER reductions increased from 36% (BEC ≥150) to 63% (BEC ≥450 cells/μL).29 The approved threshold is BEC ≥300 cells/μL, though clinically meaningful benefit extends to ≥150 cells/μL. Peak historical BEC—often obscured by chronic OCS suppression—may provide a more accurate representation of eosinophilic disease burden than a single screening value. Composite Clinical Predictors OCS dependence, comorbid CRSwNP, reduced FVC (<65% predicted), a history of ≥3 exacerbations per year, and late-onset asthma (>40 years at diagnosis) are each independently associated with enhanced benralizumab responsiveness in pooled pivotal trial analyses.31 Conversely, higher BMI, multiple comorbidities contributing independently to respiratory symptoms (bronchiectasis, GERD, vocal cord dysfunction), and longer severe asthma disease duration predict lower remission probability in real-world studies.32 Emerging Biomarkers FeNO reflects IL-4/IL-13-driven epithelial nitric oxide synthase activity and remains elevated during benralizumab treatment despite near-complete eosinophil depletion—reflecting the non-eosinophil-dependent component of airway T2 inflammation.33 Sputum eosinophil count is dramatically reduced (>85% achieving <3% after 6 months in real-world studies), confirming bronchial compartment depletion.33 Functional imaging parameters (Xe-129 MRI VDP and CT mucus scores) independently predict ACQ-6 response to benralizumab and document airway structural improvements over 2.5 years.14 Genetic biomarkers are emerging: SNPs in FcγRIIIa (rs396991), IL-5Rα-related genes, and cytokine receptor genes have been identified as potential pharmacogenomic predictors of response to benralizumab.34 Blood basophil count ≥22 cells/μL was associated with clinical remission achievement in a Japanese cohort.35 These findings set the stage for integrated omics-guided precision biologic prescribing. Clinical Remission: A Paradigm Shift in Severe Asthma Defining Remission Clinical remission in severe asthma is defined as a composite achievement encompassing: (1) no clinically significant exacerbations; (2) no or minimal OCS use; (3) well-controlled symptoms (ACQ-6 ≤0.75 or ACT ≥20); and (4) stable or improved lung function (pre-bronchodilator FEV1 ≥80% predicted or increase ≥100 mL from baseline). Two international Delphi consensus documents have codified this framework, and the concept of “complete” versus “partial” remission (three of four criteria) has been operationalized in multiple real-world and trial analyses.8,9 Remission in Phase 3 Trials A landmark post hoc analysis of pooled SIROCCO/CALIMA data applied composite remission criteria to patients treated for 12 months. Using a three-component definition (no exacerbations, no OCS, ACQ-6 <1.5), 39.2% of benralizumab-treated patients achieved remission versus 26.6% on placebo.29,36 Applying the four-component definition (adding FEV1 increase ≥100 mL), 14.5% achieved remission with benralizumab versus 7.7% with placebo.9 These rates are underestimates: SIROCCO/CALIMA protocols did not allow OCS dose reductions during the trial, precluding OCS elimination in dependent patients. Among ZONDA patients, 22.5% on benralizumab versus 7.5% on placebo achieved four-component remission at 6 months. Baseline characteristics predicting remission included higher BEC (median 412 vs 365 cells/μL in non-remitters), FEV1 ≥65% predicted, fewer prior exacerbations, lower ACQ-6 scores, and presence of nasal polyposis.36 Long-Term Remission Durability Analyses of BORA and MELTEMI extension data established that remission, once achieved, is durable with continued benralizumab treatment. The 2025 comprehensive review by Menzies-Gow and colleagues confirmed that patients in remission at 12 months predominantly remained in remission through years 2, 3, 4, and 5 of observation, without evidence of tolerance or waning effect.36 The ANDHI-In Practice substudy demonstrated that remission was maintained even as background medications (ICS, OCS, adjunctive controllers) were progressively reduced.37 Real-World Remission Evidence Real-world studies across multiple countries and healthcare systems demonstrate that clinical remission is achievable in routine practice, not merely in tightly controlled trial conditions. A multinational Spanish cohort (n=204) reported 44.1% remission at 12 months.38 An Italian multicenter cohort (n=164) found 42.1% sustained remission at 24 months using a four-component definition; reversibility of airflow limitation and comorbid CRSwNP were independent remission predictors.39 A UK multicenter real-world study (n=276) observed remission in 17% at 12 months and 32% at 24 months overall, rising to 28% and 49% after excluding patients with confounding non-asthmatic respiratory comorbidities.32 In extended follow-up, remission rates increase with treatment duration. An Italian three-year multicenter study (n=108) found that 84.31% achieved partial or complete remission at 36 months, with FEV1 improving by a median of 440 mL.40 A four-year single-center Italian study (n=23) found 86.9% achieving remission at 12 months, maintained at 91.3% at 48 months, with the proportion achieving complete (versus partial) remission increasing from 65% to 71% between 12 and 48 months.41 These trends suggest that remission rates continue to improve with sustained treatment and early biologic initiation. Negative predictors of remission across studies include higher BMI, maintenance OCS use, multiple comorbidities, and longer severe asthma duration prior to biologic initiation—the latter highlighting the importance of early precision therapy before irreversible structural changes accrue.32,42 A comprehensive overview of clinical evidence, remission criteria, and the evolving treatment paradigm is presented in Figure 2. Figure 2Benralizumab in Severe Eosinophilic Asthma: Clinical Evidence, Remission Criteria, and Treatment Paradigm. (A) Efficacy outcomes from pivotal phase 3 trials (SIROCCO, CALIMA, ANDHI, ZONDA, PONENTE, SHAMAL, ABRA) and the largest real-world program (XALOC-1, n=1002, 15 countries), demonstrating consistent reductions in annual exacerbation rate, OCS elimination, and ICS de-escalation across all patient subgroups. (B) Four-criterion composite clinical remission endpoint (Delphi consensus framework): no exacerbations, OCS Independence, ACQ-6 ≤0.75 or ACT ≥20, and FEV1 ≥80% predicted. Real-world remission rates increase progressively from 17–44% at 12 months to up to 91% in selected cohorts at 48 months; key positive and negative predictors identified across multinational studies. (C) Treatment paradigm shift from symptomatic escalation toward treat-to-target remission and future off-therapy disease modification; benralizumab efficacy across comorbid eosinophilic conditions (CRSwNP: nasal polyp eosinophil count reduced to 0/mm2, OSTRO; EGPA: 59% remission, MANDARA; EoE: 87% histologic response, MESSINA) and standard dosing regimen.A) Key outcomes from pivotal trials show annual exacerbation rate reduction: SIROCCO -51 percent, CALIMA -28 percent, ANDHI -49 percent. OCS elimination: ZONDA 52.7 percent, PONENTE 62.9 percent. ICS de-escalation: SHAMAL 92 percent reduced. Real-world evidence: XALOC-1 -82.7 percent AER. B) Clinical remission composite endpoint includes lung function, OCS independence, symptom control, no exacerbations. Real-world remission rates: 12 months 17-44 percent, 24-36 months 42-64 percent, 48 months up to 91 percent. Remission predictors: positive - BEC <300, negative - high BMI. C) Treatment paradigm: Escalation and suppression, treat-to-target, remission off-therapy. Eosinophilic comorbidities addressed: CRSwNP 0 eosinophils, EGPA 59 percent remission, EoE 87 percent histologic response. Dosing: 30 mg SC, Q4W x 3 loading, Q8W maintenance. References from various studies and trials are included.Infographic on benralizumab outcomes, remission criteria and treatment paradigm in eosinophilic asthma.Abbreviations: AER, annual exacerbation rate; BEC, blood eosinophil count; CRSwNP, chronic rhinosinusitis with nasal polyps; EGPA, eosinophilic granulomatosis with polyangiitis; EoE, eosinophilic esophagitis; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; OCS, oral corticosteroid; RW, real-world; SC, subcutaneous. Benralizumab in Severe Eosinophilic Asthma: Clinical Evidence, Remission Criteria, and Treatment Paradigm. (A) Efficacy outcomes from pivotal phase 3 trials (SIROCCO, CALIMA, ANDHI, ZONDA, PONENTE, SHAMAL, ABRA) and the largest real-world program (XALOC-1, n=1002, 15 countries), demonstrating consistent reductions in annual exacerbation rate, OCS elimination, and ICS de-escalation across all patient subgroups. (B) Four-criterion composite clinical remission endpoint (Delphi consensus framework): no exacerbations, OCS Independence, ACQ-6 ≤0.75 or ACT ≥20, and FEV1 ≥80% predicted. Real-world remission rates increase progressively from 17–44% at 12 months to up to 91% in selected cohorts at 48 months; key positive and negative predictors identified across multinational studies. (C) Treatment paradigm shift from symptomatic escalation toward treat-to-target remission and future off-therapy disease modification; benralizumab efficacy across comorbid eosinophilic conditions (CRSwNP: nasal polyp eosinophil count reduced to 0/mm2, OSTRO; EGPA: 59% remission, MANDARA; EoE: 87% histologic response, MESSINA) and standard dosing regimen. Benralizumab in Comorbid Eosinophilic Conditions Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) CRSwNP co-occurs in approximately 60% of SEA patients and shares the same T2-driven eosinophilic pathophysiology, representing the “unified airway” principle of upper and lower respiratory tract disease. The phase 3 OSTRO trial (n=413) demonstrated that benralizumab significantly improved nasal polyp score (NPS) and nasal blockage score versus placebo at week 40 (p≤0.005) and achieved complete depletion of nasal polyp tissue eosinophils (57.6 cells/mm2 at baseline to 0 at week 56; p<0.001), with significant reductions in eosinophil-derived neurotoxin in nasal lining fluid.18,43 In real-world clinical practice, multiple multinational studies confirm that patients with comorbid SEA + CRSwNP receiving benralizumab achieve clinically meaningful improvements in SNOT-22 (15–20 points), NPS (1–2 points), and olfactory function, with reduced polyp recurrence requiring surgery.44,45 The RANS multinational real-world study (n=233) reported 49.1% achieving meaningful NPS improvement and 67.6% achieving SNOT-22 improvement at 12 months.46 Importantly, SEA + CRSwNP patients consistently derive enhanced asthma outcomes (lower exacerbation rates, greater OCS reductions) compared to SEA alone, consistent with the greater T2 inflammatory burden in comorbid disease.47 Eosinophilic Granulomatosis with Polyangiitis (EGPA) The phase 3 MANDARA trial (n=140) established benralizumab as non-inferior to mepolizumab for EGPA induction of remission (59% vs 56%; difference 3 pp; p=0.73 for superiority).48 Benralizumab achieved greater OCS elimination (41% vs 26%) and more profound blood eosinophil suppression, consistent with its mechanism. Safety was favorable: benralizumab produced fewer serious adverse events (6% vs 13%). A meta-analysis of eight EGPA studies (n=396) confirmed complete remission in 56.8% of pooled patients and a mean OCS reduction of −8.25 mg/day.49 Long-term real-world data up to 36 months demonstrate increasing remission rates (39% → 65%), confirming durable EGPA disease control.50 Eosinophilic Esophagitis (EoE) The phase 3 MESSINA trial (n=211) demonstrated that benralizumab produced histologic response (≤6 eosinophils/high-power field) in 87.4% versus 6.5% on placebo (p<0.001)—a remarkable degree of mucosal eosinophil clearance.51 However, the trial did not achieve significant Dysphagia Symptom Questionnaire improvement, suggesting that symptom burden in EoE is driven by structural fibrotic changes and neural sensitization beyond active eosinophilic infiltration. Real-world case reports document sustained EoE remission with long-term benralizumab, with no recurrence in select patients after treatment discontinuation.52 COPD with Eosinophilic Endotype GALATHEA and TERRANOVA were two large phase 3 randomised trials evaluating benralizumab as add-on therapy in moderate-to-very-severe COPD with a history of exacerbations; neither met its primary endpoint of a significant reduction in the annual COPD exacerbation rate versus placebo. However, exploratory analyses identified a subgroup with BEC ≥220 cells/μL combined with ≥3 prior exacerbations, more severe airflow limitation, or greater bronchodilator reversibility who derived meaningful AER reduction with benralizumab 100 mg Q8W (RR 0.69–0.76).53 These findings are hypothesis-generating only; benralizumab is not approved for COPD, and whether a prospectively defined eosinophilic COPD endotype benefits from IL-5Rα blockade remains to be confirmed in dedicated trials. Real-World Effectiveness Overview and Major Registries Real-world evidence from observational studies, national registries, and multinational databases consistently corroborates and in many instances exceeds the effect sizes observed in the pivotal trials, potentially reflecting patient selection toward higher eosinophilic burden in clinical practice. In the UK-based Wessex Severe Asthma Cohort, 130 patients demonstrated a 72.8% reduction in AER at 48 weeks; 43.8% were exacerbation-free, and 51.4% of OCS-dependent patients eliminated maintenance OCS.54 The ZEPHYR 2 large US insurance claims database study (n=429) demonstrated 52–64% AER reductions across all eosinophil subgroups, including patients with BEC <150 cells/μL.55 The XALOC-1 multinational program (n=1,002, 15 countries, 48 weeks)—to date the largest real-world benralizumab study—reported 71.3% exacerbation-free rates at week 48 (versus 17.2% at baseline), an 82.7% overall AER reduction, and OCS elimination in 47.4% of OCS-dependent patients.56 Results were consistent across all key clinical subgroups: biologic-naïve versus biologic-experienced, BEC levels, presence of CRSwNP, OCS dependence, and age of asthma onset.57 The prospective XALOC-2 program (n=535) documented early benefits: 58% achieved MCID (≥0.5 point) ACQ reduction at week 1, rising to 78.6% at week 56, with 26.7% achieving three-component clinical remission by week.56,57 Lung Function Recovery Real-world FEV1 improvements have frequently exceeded those documented in RCTs, likely reflecting the selection of patients with more reversible obstruction and greater eosinophil burdens. A series of Italian real-world studies reported FEV1 increases of 400–1,080 mL in patients with BEC >500 cells/μL and/or comorbid CRSwNP.58 Full-body plethysmography studies confirm significant reductions in residual volume (−30%), intrathoracic gas volume (−17%), and airway resistance (−100% normalization) at 6 months, documenting resolution of dynamic hyperinflation and air trapping beyond what spirometry alone captures.59 Biologic-Experienced Patients Data from international registries indicate that benralizumab became the most frequently initiated biologic globally by 2019, with omalizumab-to-anti-IL-5/5R the most common switch pattern.60 Switching to benralizumab from both omalizumab and mepolizumab yields meaningful additional clinical benefit in the majority of patients, including those who were previous non-responders or late non-responders.61,62 The ANANKE Italian multicenter study (n=162 total) reported >87% AER reduction and >94% severe AER reduction in both biologic-naïve and biologic-experienced subgroups at 96 weeks.63 In the subset switched specifically from mepolizumab due to waning response, benralizumab produced 100% OCS dose reduction, suggesting that more complete IL-5Rα blockade overcomes inadequate ligand-level suppression.63 Safety Profile and Long-Term Tolerability Overall Safety Across the complete clinical development program—encompassing phase 3 pivotal trials, extension studies, and phase 3b/4 investigations—benralizumab has demonstrated a consistently favorable and predictable safety profile. Common adverse events in trials included viral upper respiratory tract infection (14–16%), nasopharyngitis, headache, sinusitis, and worsening asthma, all occurring at frequencies similar to placebo groups. Serious adverse events were uncommon (worsening asthma 3–4%, pneumonia <1%), and no imbalance in serious infections, opportunistic infections, or malignancies was observed between treatment and placebo groups.22,23 Long-Term Safety of Eosinophil Depletion The five-year MELTEMI data provide the most definitive evidence on long-term eosinophil depletion safety. Adverse event and serious adverse event rates remained stable over 5 years without accumulation, and no consequences attributable to chronic eosinophil depletion were identified.23 The dedicated 48-month real-world safety study (n=123) documented only 1.6% of adverse events as treatment-related, with one serious adverse event (vagal hypotension) attributed to benralizumab.64 No increase in parasitic infections, malignancies, or impaired healing was identified across any major safety dataset.29 Adrenal Function Management The PONENTE trial’s finding of adrenal insufficiency in 60% of patients at the time of OCS tapering initiation underscores the critical importance of systematic HPA axis evaluation when de-escalating OCS with the support of benralizumab.25 The structured adrenal assessment protocol—morning cortisol, followed by ACTH stimulation if indicated—enables safe OCS tapering while detecting patients who require a longer, more gradual reduction schedule. Clinicians managing OCS-dependent SEA patients initiating benralizumab should incorporate routine adrenal function testing into their treatment protocols. Changing Treatment Paradigms: From Symptom Control to Treat-to-Target The Pre-Biologic Era and the Paradigm Shift Prior to precision biologics, severe asthma management was characterized by progressive pharmacological escalation—adding LAMA, leukotriene antagonists, theophylline, and ultimately maintenance OCS—with the pragmatic acceptance of persistent exacerbations, lung function loss, and accumulating OCS toxicity as inevitable sequelae. This approach was symptom-suppressive rather than disease-modifying. Benralizumab has disrupted this paradigm at multiple levels. First, by eliminating eosinophilic inflammation rather than symptomatically managing its consequences, benralizumab interrupts the pathogenic cascade at its root.65 Second, the achievement of disease control sufficient to permit progressive de-escalation of background medications—from OCS, to reduction of high-dose ICS, to as-needed ICS only (SHAMAL)—represents a step-down therapy model previously considered impossible in severe asthma.26 Third, the growing evidence that a proportion of patients achieve and sustain clinical remission—the composite achievement of exacerbation freedom, OCS independence, symptom control, and lung function preservation—has legitimized remission as a realistic treatment goal rather than an aspirational ideal.66,67 While this paradigm shift is a class-wide phenomenon driven by several type-2 biologics, benralizumab is emphasised here because its development programme most fully exemplifies each successive step—from exacerbation reduction to OCS elimination, ICS de-escalation, and structured treat-to-target management. Treat-to-Target Implementation Treat-to-target in severe asthma proposes that treatment should be initiated, adjusted, and switched until a pre-defined composite target (remission) is achieved, with structured reassessment at defined intervals. The predictors of remission achievement with benralizumab—higher BEC, lower BMI, preserved lung function, nasal polyposis, shorter severe asthma duration, absence of confounding comorbidities—constitute a clinical profile that can be identified at diagnosis, enabling proactive, individualized treatment planning. Early biologic initiation emerges as a critical determinant of remission: each additional year of severe asthma phase reduces remission odds by approximately 10%, directly challenging current prescribing thresholds that mandate escalating pharmacological treatment prior to biologic eligibility.42 Revised international severe asthma guidelines should incorporate earlier biologic access criteria to maximize the population-level impact of clinical remission. Biologic Selection Framework With six approved biologics across four mechanistic classes, biologic selection has become increasingly nuanced. Benralizumab offers distinct advantages for: (1) patients with high BEC (≥300–450 cells/μL) as the primary driver; (2) those with comorbid CRSwNP where a single biologic can address both conditions; (3) OCS-dependent patients where robust OCS elimination is prioritized; (4) patients for whom less frequent injection (Q8W) enhances treatment adherence; and (5) biologic-experienced patients who have achieved suboptimal results with anti-IL-5 ligand or anti-IgE therapy.68 Dupilumab (anti-IL-4/IL-13) and tezepelumab (anti-TSLP) offer complementary mechanisms targeting T2 inflammation beyond the IL-5 axis, and may be preferred in patients with moderate eosinophilia combined with high FeNO, coexistent atopic dermatitis, or where upstream T2 pathway blockade is desired. Comparative effectiveness data from head-to-head RCTs are urgently needed to definitively guide these decisions. Limitations and Considerations for Interpretation Several caveats temper the interpretation of the evidence summarised here. First, much of the long-term and comparative benralizumab evidence derives from open-label extension studies (BORA, MELTEMI) and post-hoc analyses of the pivotal trials rather than from prospective, remission-focused randomised designs; such data are hypothesis-generating and susceptible to survivorship and selection effects. Second, real-world studies, although valuable for external validity, are heterogeneous in design, patient selection, follow-up duration, and outcome ascertainment, and are prone to selection bias toward patients with higher eosinophilic burden or better adherence, which may inflate apparent effectiveness relative to trial populations. Third, reported clinical-remission rates vary widely (from roughly 17% to more than 90%), in part because studies apply different composite definitions—differing in the lung-function threshold, the symptom instrument and cut-off, the handling of low-dose maintenance OCS, and the required duration of sustained control—so cross-study comparisons should be made with caution and pooled figures interpreted as ranges rather than point estimates. Fourth, direct head-to-head randomised comparisons between benralizumab and other type-2 biologics are largely lacking (with the notable exception of MANDARA in EGPA), so statements of relative efficacy across agents rest largely on indirect and cross-trial comparisons. Finally, the GALATHEA and TERRANOVA programmes did not meet their primary endpoints in COPD, underscoring that eosinophil-directed efficacy is not uniform across eosinophilic airway diseases and that endotype-based patient selection remains to be prospectively validated. These considerations argue for a measured interpretation of the evidence and for adequately powered, prospective, and comparative studies employing harmonised remission definitions. Future Directions and Unresolved Questions Several key areas warrant ongoing investigation. First, the durability of clinical remission after planned benralizumab discontinuation—“remission off-therapy” —remains uncertain. Most patients experience disease relapse after cessation, but select reports of sustained remission after prolonged treatment suggest a disease-modifying potential that deserves prospective evaluation in structured withdrawal trials. Second, integrated multi-omic biomarker strategies—combining BEC, FeNO, serum proteomics, imaging biomarkers (Xe-129 MRI VDP, CT mucus score), and pharmacogenomics (FcγRIIIa SNPs)—hold promise for individualized biologic prescription, remission prediction, and treatment decision algorithms beyond current clinical practice. Third, the role of combination biologic therapy—addressing multiple cytokine pathways simultaneously—deserves formal RCT evaluation in patients failing single-agent treatment, given case series suggesting benefit in overlapping T2 phenotypes.69 Fourth, age-related considerations—including dedicated pediatric pharmacokinetic and safety studies in children aged 6–11 years, pregnancy outcomes in OCS-dependent patients continuing benralizumab, and the impact of obesity (a known negative predictor of remission) on benralizumab pharmacodynamics — require dedicated investigation. Fifth, digital health integration—remote monitoring of peak expiratory flow, symptom burden, and early exacerbation signals—could enable adaptive treat-to-target implementation in routine clinical practice, optimizing the timing of biologic reassessment and background medication reduction. Conclusion Benralizumab has established itself as a cornerstone of precision medicine in severe eosinophilic asthma, substantially influencing both the approach to treatment and the expectations of outcomes. Its unique dual mechanism—IL-5Rα receptor blockade combined with afucosylation-enhanced ADCC—achieves near-complete, rapid, and sustained depletion of eosinophils and basophils from blood, bone marrow, and airway tissue, producing one of the most extensive anti-eosinophilic effects among currently approved biologics. The pivotal phase 3 clinical program (SIROCCO, CALIMA, ZONDA) established benralizumab’s efficacy across the spectrum of severe eosinophilic asthma, from exacerbation-prone patients on high-dose ICS to OCS-dependent patients. Long-term safety over five years (MELTEMI) confirms an excellent tolerability profile without consequences from chronic eosinophil depletion. Landmark studies including PONENTE, SHAMAL, and ABRA have further extended benralizumab’s clinical impact: enabling safe and structured OCS elimination in the majority of dependent patients, demonstrating that well-controlled patients can reduce ICS to as-needed therapy, and establishing biologic-based treatment of acute eosinophilic exacerbations as a new paradigm. The emergence of clinical remission as a realistic and measurable therapeutic goal represents benralizumab’s most transformative contribution to severe asthma management. Real-world studies across multiple countries report remission rates of 17–44% at 12 months and up to 91% at 48 months in selected cohorts—rates that improve with earlier biologic initiation, sustained treatment, and progressive background medication reduction. These findings support consideration of revised treatment guidelines incorporating earlier biologic-access thresholds and structured treat-to-target reassessment protocols, pending confirmation in prospective studies. Beyond asthma, benralizumab demonstrates clinically meaningful activity in comorbid CRSwNP (addressing the unified airway simultaneously), EGPA (non-inferior to mepolizumab with superior OCS elimination), eosinophilic esophagitis (near-complete histological remission), and potentially a defined eosinophilic COPD endotype. This breadth of eosinophilic disease activity reinforces benralizumab’s position as one of the most broadly active anti-eosinophilic biologics available. As the severe asthma biologic landscape continues to mature, the strategic positioning of benralizumab within a patient-centered, biomarker-guided, treat-to-target framework is increasingly well-defined. The next frontier—remission off-therapy, combination strategies, and integrated omics precision selection— promises to further advance the goal of making clinical remission the expected, rather than exceptional, outcome in severe eosinophilic asthma.